【作者单位】1 Department of Spine Surgery & Musculoskeletal Tumor, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China; 2 These authors contributed equally to this work.; 3 College of Science, Research Center for Ecology, Laboratory of Extreme Environmental Biological Resources and Adaptive Evolution, Tibet University, Lhasa 850000, China; 4 Center for Experimental Basic Medical Education, Institute of Myocardial Injury and Repair, Department of Cardiology, Zhongnan Hosipital of Wuhan University, Wuhan 430071, China; 5 Jiangxi Key Laboratory of Organo-Pharmaceutical Chemistry, Chemistry and Chemical Engineering College, Gannan Normal University, Ganzhou 341000, China; 6 Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan 430071, China; 7 State Key Laboratory of Virology, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, China; 8 Shenzhen Institute of Wuhan University, Shenzhen 518057, China
【摘要】 DNA damage response inhibitors potentiate the therapeutic efficacy in osteosarcoma treatment. However, drug resistance, severe collateral toxicity, and poor bioavailability of DDR inhibitors in vivo are the main challenges. The NIR-II fluorescence ...
